A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry

Spelman T., ÖZAKBAŞ S., Alroughani R., Terzi M., Hodgkinson S., Laureys G., ...Daha Fazla

Neurodegenerative Disease Management, cilt.13, sa.4, ss.215-221, 2023 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 13 Sayı: 4
  • Basım Tarihi: 2023
  • Doi Numarası: 10.2217/nmt-2023-0005
  • Dergi Adı: Neurodegenerative Disease Management
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, CINAHL, MEDLINE
  • Sayfa Sayıları: ss.215-221
  • Anahtar Kelimeler: cladribine tablets, dimethyl fumarate (Tecfidera®), fingolimod (Gilenya®), lay summary, multiple sclerosis, relapses, teriflunomide (Aubagio®), treatment options
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

What is this summary about? Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries. Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad®) compared with other oral treatments. What were the results? Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS. What do the results mean? The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.